Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis

International Immunopharmacology

Volumn 9, Issue 2, 2009, Pages 230-240

  Huh, Jeong Eun ^a   Baek, Yong Hyeon ^b   Ryu, Seong Ryong ^a   Lee, Jae Dong ^a   Choi, Do Young ^a   Park, Dong Suk ^b  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Anti inflammation; Cartilage protection; KHBJ 9B; Osteoarthritis; Triterpenoids

Indexed keywords

AGGRECANASE; ANTIRHEUMATIC AGENT; ARALIA CORDATA EXTRACT; BETULA PLATYPHYLLA EXTRACT; BETULIC ACID; BETULIN; CATECHIN; CELECOXIB; COLLAGEN TYPE 11; COLLAGEN TYPE 2; COLLAGENASE; COLLAGENASE 3; EPICATECHIN; GAG PROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; KHBJ 9B; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PIMARADIENOIC ACID; PLANT EXTRACT; POLYPHENOL DERIVATIVE; PROTEOGLYCAN; RECOMBINANT INTERLEUKIN 1BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CHEMICAL COMPOSITION; COLLAGEN DEGRADATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MALE; NONHUMAN; OSTEOARTHRITIS; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; RABBIT;

AGED; AGED, 80 AND OVER; ANIMALS; ARALIA; BETULA; CARTILAGE, ARTICULAR; CELLS, CULTURED; COLLAGEN TYPE II; COLLAGENASES; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INTERLEUKIN-1BETA; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PEPTIDE HYDROLASES; PHYTOTHERAPY; RABBITS; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58649093500     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.11.016     Document Type: Article

References (49)

1. Poole R. An introduction to the pathophysiology of osteoarthritis. Front Biosci 4 (1999) D 6662-70
2. Glasson S.S. In vivo osteoarthritis target validation utilizing genetically-modified mice. Current Drug Targets 8 (2007) 367-376
3. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoerrner L.A., Hutchinson N.I., et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 100 (1997) 93-106
4. Gendron C., Kashiwagi M., Hughes C., Caterson B., and Nagase H. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 555 (2003) 431-436
5. Westling J., Fosang A.J., Last K., Thompson V.P., Tomkinson K.N., Hebert T., et al. ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain. J Biol Chem 277 (2002) 16059-16066
6. Sandy J.D., Neame P.J., Boynton R.E., and Flannery C.R. Catabolism of aggrecan in cartilage explants: identification of a major cleavage site within the interglobular domain. J Biol Chem 266 (1991) 8683-8685
7. Powell A.J., Little C.B., and Hughes C.E. Low molecular weight isoforms of the aggrecanases are responsible for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system. Arthritis Rheumatism 56 (2007) 3010-3019
8. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 9 (2001) 539-552
9. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., and Woessner J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84 (1989) 678-685
10. Burrage P.S., Mix K.S., and Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front Biosci 11 (2006) 529-543
11. Westacott C.I., and Sharif M. Cytokines in osteoarthritis: mediators on markers of joint destruction. Semin Arthritis Rheum 25 (1996) 254-272
12. Dumond H., Presle N., Pottie P., Pacquelet S., Terlain B., Netter P., et al. Site specific change in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 284-295
13. Kim J.H., Ryu K.H., Jung K.W., Han C.K., Kwak W.J., and Cho Y.B. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explants culture. J Pharmacol Sci 98 (2005) 298-306
14. Mitchell P.G., Magna H.A., Reeves L.M., Lopresti-Morrow L.L., Yocum S.A., Rosner P.J., et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97 (1996) 761-768
15. Billinghurst R.C., Wu W., Ionescu M., Reiner A., Dahlberg L., Chen J., et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum 43 (2000) 664-672
16. Dahlberg L., Billinghurst R.C., Manner P., Nelson F., Webb G., Ionescu M., et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 43 (2000) 673-682
17. Kashiwagi M., Tortorella M., Nagase H., and Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276 (2001) 12501-12504
18. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 494 (2001) 192-195
19. Nagase H., and Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 5 (2003) 94-103
20. Hardy M.M., Seibert K., Manning P.T., Currie M.G., Woerner B.M., Edwards D., et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46 (2002) 1789-1803
21. Fung H.B., and Kirschenbaum H.L. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin Ther 21 (1999) 1131-1157
22. Lazzaroni M., and Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 20 Suppl. 2 (2004) 48-58
23. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
24. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
25. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
26. Baek Y.H., Huh J.E., Lee J.D., Choi D.Y., and Park D.S. Effect of Aralia cordata extracts on cartilage protection and apoptosis inhibition. Biol Pharm Bull 29 (2006) 1423-1430
27. Huh J. Dong Ui Bo Gam [The precious mirror of oriental medicine] (1999), Namsangdang, Seoul 1613 A.D
28. Kikuchi T., Sakuta T., and Yamaguchi T. Intra-articular injection of collagenase induces experimental osteoarthritis in mature rabbits. Osteoarthritis Cartilage. 6 (1998) 177-186
29. Colombo C., Butler M., O'Byrne E., Hickman L., Swartzendruber D., Selwyn M., et al. A new model of osteoarthritis in rabbits. I. Development of knee joint pathology following lateral meniscectomy and section of the fibular collateral and sesamoid ligaments. Arthritis Rheum 26 (1983) 875-886
30. Kikuchi T., Yamada H., and Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 4 (1996) 99-110
31. Pastoureau P., Leduc S., Chomel A., and De Ceuninck F. Quantitative assessment of articular cartilage and subchondral bone histology in the meniscectomized guinea pig model of osteoarthritis. Osteoarthritis Cartilage 11 (2003) 412-423
32. Sabatini M., Lesur C., Thomas M., Chomel A., Anract P., de Nanteuil G., et al. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum 52 (2005) 171-180
33. Tapsell L.C., Hemphill I., Cobiac L., Patch C.S., Sullivan D.R., Fenech M., et al. Health benefits of herbs and spices: the past, the present, the future. Med J Aust 185 (2006) S4-24
34. Marcus D.M., and Grollman A.P. Botanical medicines-the need for new regulations. N Engl J Med 347 (2002) 2073-2076
35. Okuyama E., Nishimura S., and Yamazaki M. Analgesic principles from Aralia cordata Thunb. Chem Pharm Bull 39 (1991) 405-407
36. Dang N.H., Zhang X., Zheng M., Son K.H., Chang H.W., Kim H.P., et al. Inhibitory constituents against cyclooxygenases from Aralia cordata Thunb. Arch Pharm Res 28 (2005) 28-33
37. Yogeeswari P., and Sriram D. Betulinic acid and its derivatives: a review on their biological properties. Curr Med Chem 12 (2005) 657-666
38. Demeule M., Brossard M., Pagé M., Gingras D., and Béliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478 (2000) 51-60
39. Garbisa S., Biggin S., Cavallarin N., Sartor L., Benelli R., and Albini A. Tumor invasion: molecular shears blunted by green tea. Nature Med 5 (2000) 1216
40. Garbisa S., Sartor L., Biggin S., Salvato B., Benelli R., and Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 91 (2001) 822-832
41. Kennedy D.O., Kojima A., Yano Y., Hasuma T., Otani S., and Matsui-Yuasa I. Growth inhibitory effect of green tea extract in Ehrlich ascites tumor cells involves cytochrome c release and caspase activation. Cancer Lett 166 (2001) 9-15
42. Imai K., and Nakach K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Br Med 310 (1995) 693-696
43. Isiguro N., Ito T., Iwata H., Jugessur H., Ionescu M., and Poole A.R. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 42 (1999) 129-136
44. Fosang A.J., Last K., and Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 98 (1996) 2292-2299
45. Majumdar M.K., Askew R., Schelling S., Stedman N., Blanchet T., Hopkins B., et al. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 56 (2007) 3670-3674
46. El Hajjaji H., Marcelis A., Devogelaer J.P., and Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30 (2003) 2444-2451
47. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13 (2005) 519-526
48. Mastbergen S.C., Marijnissen A.C., Vianen M.E., Zoer B., van Roermund P.M., Bijlsma J.W., et al. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology (Oxford) 45 (2006) 405-413
49. Mastbergen S.C., Jansen N.W., Bijlsma J.W., and Lafeber F.P. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 8 (2006) R2